DmitriyZamarinMDPhD

Oncology • New York, NY

Gynecologic Cancer

Section Head, Gynecologic Medical Oncology

Join to view full profile

Dr. Zamarin is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Zamarin's full profile

Already have an account?

Office
Icahn School of Medicine at Mount Sinai
1470 Madison Ave
New York, NY 10029

Summary

I am a medical oncologist specializing in the care of women with gynecologic cancers, including cervical, ovarian, and endometrial cancers. My clinical and laboratory research is focused on the development of novel ways to use the immune system to treat cancer. In addition, I have a special interest in genetically engineered oncolytic viruses, an emerging class of immune therapeutic drugs. By manipulating the oncolytic viruses and the immune system, I’m exploring different ways to enhance the immune recognition of tumors and to develop novel treatment strategies for gynecologic cancers.

Education & Training

Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 2010 - 2014
Icahn School of Medicine at Mount Sinai/Mount Sinai HospitalResidency, Internal Medicine, 2008 - 2010
Icahn School of Medicine at Mount SinaiClass of 2008

Certifications & Licensure

FL State Medical License 2021 - Present
NJ State Medical License 2019 - 2025
NY State Medical License 2009 - 2025
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

Liz Tilberis Early Career Award Ovarian Cancer Research Alliance
GOG Foundation Scholar Investigator Award GOG Foundation, 2019
MSKCC Academic Excellence Recognition Award Memorial Sloan Kettering Cancer Center, 2018
Judith Liebenthal Robinson Ovarian Cancer Foundation Award Foundation for Women's Cancers, 2015
Bladder Cancer Awareness Network Young Investigator Award Bladder Cancer Awareness Network, 2014
Conquer Cancer Foundation ASCO Young Investigator Award Conquer Cancer Foundation, 2013
Damon Runyon Foundation Fellowship Award Damon Runyon Foundation, 2012
Celgene Future Leaders in Hematology Award Celgene, 2012
American Society of Hematology Abstract Achievement Award American Society of Hematology, 2011
Department of Medicine Award for excellence in research Mount Sinai School of Medicine, 2010
Harold Elster Memorial Prize for Highest Academic Standing Mount Sinai School of Medicine, 2008
Barry Coller Award for Excellence in Clinical Medicine Mount Sinai School of Medicine, 2008
Alpha Omega Alpha Mount Sinai School of Medicine, 2008
Graduate Student Conference Travel Awards Mount Sinai School of Medicine, 2004-2008
Award for Best Doctoral Dissertation Mount Sinai School of Medicine, 2006
American Society for Virology Travel Award American Society for Virology, 2005
Teaching Assistant Award Mount Sinai School of Medicine, 2005
Academic Excellence Award Mount Sinai School of Medicine, 2003
Student Service Award Mount Sinai School of Medicine, 2002
Summa Cum Laude Manhattan College, 2000
Phi Beta Kappa Manhattan College, 1999
Join now to see all

Clinical Trials

A Study of Carboplatin and Paclitaxel Chemotherapy With Nivolumab With or Without Ipilimumab in Patients With Ovarian Cancer Start of enrollment: 2017 Aug 04
Active, not recruiting
Phase 1
Study of Pembrolizumab Following Surgery in Patients With Microsatellite Instability High (MSI-H) Solid Tumors Start of enrollment: 2019 Feb 20
Active, not recruiting
Early Phase 1
Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to the Usual Radiation Treatment for Newly Diagnosed Early Stage High Intermediate Risk Endometrial Cancer Start of enrollment: 2020 Apr 09
Active, not recruiting
Phase 3
ZW25 in Women With Endometrial Cancers Start of enrollment: 2020 Aug 12
Completed
Phase 2
A Study of MEDI9253 in Combination With Durvalumab in Select Solid Tumors Start of enrollment: 2020 Dec 02
Completed
Phase 1
Radiation and TSR-042 (Dostarlimab) in People With Endometrial Cancer After They Receive Surgery Start of enrollment: 2021 Apr 02
Active, not recruiting
Phase 2
Phase 1a/1b Study of STK-012 Monotherapy and in Combination With Pembrolizumab in Patients With Solid Tumors Start of enrollment: 2022 Jan 25
Recruiting
Phase 1
Roles: Contact
Join now to see all

Publications & Presentations

PubMed

Phase I study of a recombinant attenuated oncolytic virus, MEDI5395 (NDV-GM-CSF), administered systemically in combination with durvalumab in patients with advanced so...
Diwakar Davar, Benedito A Carneiro, Grace K Dy, Siddharth Sheth, Mitesh J Borad
Journal for Immunotherapy of Cancer. 2024-11-17
Transgelin 2 guards T cell lipid metabolism and antitumour function.
Sung-Min Hwang, Deepika Awasthi, Jieun Jeong, Tito A Sandoval, Chang-Suk Chae
Nature. 2024-11-01
Ovarian cancer-derived IL-4 promotes immunotherapy resistance.
Gurkan Mollaoglu, Alexander Tepper, Chiara Falcomatà, Hunter T Potak, Luisanna Pia
Cell. 2024-10-30

Journal Articles

A Phase 1 Dose-Escalation Study of Intraperitoneal Cisplatin, intravenous/intraperitoneal Paclitaxel, Bevacizumab, and Olaparib for Newly Diagnosed Ovarian Cancer
Karen A Cadoo, Roisin E O'Cearbhaill, Dmitriy Zamarin, Paul J Sabbatini, William P Tew, Carol Aghajanian, Jason A Konner, Gynecologic Oncology

Press Mentions

Mount Sinai Launches Center of Excellence to Enhance Treatment and Care for Patients with Gynecologic CancerSeptember 16th, 2024
Key Advances and Advocacy Are Themes at SGO Annual MeetingMarch 21st, 2023
Dmitriy Zamarin, MD, PhD, on Novel Therapies for Cervical CancerMarch 23rd, 2022
Join now to see all

Grant Support

GOG Foundation Scholar Investigator AwardGOG Foundation2019–2024
Profiling co‑evolution of ovarian cancer and its immune microenvironmentOvarian Cancer Research Alliance2020–2022
Chromatin remodeling and immunotherapy in ovarian cancerOvarian Cancer Research Alliance2020–2022
Novel approaches to locoregional and systemic immunotherapy for ovarian cancerCongressionally Directed Medical Research Programs: Ovarian Cancer Academy (OCA)2016–2021

Committees

Chair, Translational Science, NRG Oncology Cervical Cancer Committee 2018 - Present
Member, NRG Oncology Developmental Therapeutics Committee 2018 - Present
Member, Institutional Biosafety Committee 2016 - Present
Member, Protocol Development Committee 2015 - Present
Member, Pharmacy and Therapeutics Committee, MSKCC 2014 - Present